Navigation Links
Simcere Pharmaceutical Group Reports Preliminary Unaudited Third Quarter 2013 Results
Date:11/14/2013

NANJING, China, Nov. 14, 2013 /PRNewswire/ -- Simcere Pharmaceutical Group ("Simcere" or the "Company") (NYSE: SCR), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today reported preliminary unaudited financial results for the quarter ended September 30, 2013.

Highlights
Revenue from continuing operations for the third quarter of 2013 was RMB421.3 million (US$68.8 million), a decrease of 16.5% compared to RMB504.7 million for the same period in 2012. Revenue from continuing operations for the first nine months of 2013 was RMB1,408.2 million (US$230.1 million), a decrease of 3.8% from RMB1,463.8 million for the same period in 2012.

Gross margin from continuing operations for the third quarter of 2013 decreased to 76.0% compared to 84.2% for the same period in 2012. For the first nine months of 2013, gross margin decreased to 79.9% compared to 83.9% for the same period in 2012.

Operating loss from continuing operations was RMB125.5 million (US$20.5 million) for the third quarter of 2013, compared to operating income from continuing operations of RMB26.5 million for the same period in 2012. The operating loss was primarily due to the impairment charge for  goodwill and intangible assets along with the inventory write-down for the vaccine reporting unit in the third quarter of 2013.Operating loss from continuing operations was RMB73.2 million (US$12.0 million) for the first nine months of 2013, compared to operating income from continuing operations of RMB98.4 million for the same period in 2012.

Net income attributable to Simcere from continuing operations for the third quarter of 2013 was RMB167.0 million (US$27.3 million), an increase of 944.2% from RMB16.0 million for the same period in 2012, primarily
'/>"/>

SOURCE Simcere Pharmaceutical Group
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. Simcere Pharmaceutical Group to Announce Third Quarter 2013 Financial Results on Thursday, November 14, 2013
2. Simcere Pharmaceutical Group Enters Into Definitive Merger Agreement for Going Private Transaction
3. Simcere Pharmaceutical Group Reports Preliminary Unaudited Second Quarter 2013 Results
4. Simcere Pharmaceutical Group to Announce Second Quarter 2013 Financial Results on Tuesday, August 13, 2013
5. Simcere Pharmaceutical Group Announces Sale of Equity Interest in Boda
6. Bristol-Myers Squibb and Simcere Enter Partnership to Co-Develop and Co-Commercialize Orencia(R) SC (abatacept) in China
7. Simcere Pharmaceutical Group Announces Resignation of Chief Scientific Officer
8. Simcere Pharmaceutical Group Reports Preliminary Unaudited First Quarter 2013 Results
9. Simcere Pharmaceutical Group Filed 2012 Annual Report on Form 20-F
10. Simcere Pharmaceutical Group to Announce First Quarter 2013 Financial Results on Thursday, May 9, 2013
11. Simcere Pharmaceutical Group Announces its Special Committees Engagement of Financial Advisor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... WORTH, Texas , Jan. 15, 2014  Humberto C. ... Dermatology Achievement Award" from the Journal of Drugs ... Aesthetic & Clinical Conference (ODAC). The event is January 17-20, ... Florida . The ODAC ...
(Date:1/15/2014)... PALM BEACH GARDENS, Fla. , Jan. 15, 2014  In an ... C. difficile and TB in ambulances and other transport vehicles, an ... being used by rescue personnel for the first time. ... coming in contact with these deadly pathogens, West Palm ...
(Date:1/15/2014)... 2014  Echo Therapeutics, Inc. (Nasdaq: ECTE ) ... System as a non-invasive, wireless continuous glucose monitoring system, ... Chairman and Interim CEO of Echo Therapeutics, will present ... Conference. Mr. Doman will make a ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Superbugs No Longer Ride In Rescue Vehicles 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3
... TRU-016 Produces Significant Anti-Tumor Activity and Long-Term Tumor ... Regression ... Pharmaceuticals Inc.,(Nasdaq: TRBN ) today announced presentation of ... activity and induces,significant long-term tumor eradication in a human ...
... Encouraging Results for a Potential New Front-Line Treatment ... ... Genzyme Corp.,(Nasdaq: GENZ ) reported preliminary data today from a ... as a single agent in previously untreated, older adult,patients with acute ...
Cached Medicine Technology:Trubion Announces Presentation of Positive TRU-016 Data at ASCO 2Trubion Announces Presentation of Positive TRU-016 Data at ASCO 3Trubion Announces Presentation of Positive TRU-016 Data at ASCO 4Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients 2Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients 3Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients 4Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients 5Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients 6Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients 7Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients 8
(Date:4/17/2014)... a study published today in PLOS Pathogens , ... malaria is common can mount an immune response to ... avoid repeated bouts of high fever and illness and ... bloodstream. The findings may help researchers develop future interventions ... malaria parasite. , Each year, approximately 200 million cases ...
(Date:4/17/2014)... of California, San Diego School of Medicine report that ... a recent major loss are more likely to be ... study is published in this month,s issue of the ... compassionate behaviors are associated with better health and well-being ... ways to improve the outcomes of individuals whose deficits ...
(Date:4/17/2014)... NY In a review published in the April ... president of The Feinstein Institute for Medical Research, says ... medical community,s approach to treating sepsis, which ... Americans. , Sepsis occurs when molecules released into the ... throughout the body. Inflammation is necessary for maintaining good ...
(Date:4/17/2014)... biology team has created a new technology for ... could travel the body and selectively target cancer ... biological devices that monitor and modify human physiology ... However, no existing technology enabled bioengineers to build ... and respond in a customized fashion. , "The ...
(Date:4/17/2014)... Il. (April 17, 2014) Doctors who treat ... called lymphangioleiomyomatosis (LAM) can face an agonizing treatment ... of the disease and help relieve shortness of ... transplants, and sirolimus can cause potentially fatal complications ... pulmonologist Dr. Daniel Dilling, medical director of Loyola ...
Breaking Medicine News(10 mins):Health News:Study sheds light on how the immune system protects children from malaria 2Health News:The ilk of human kindness 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Building 'smart' cell-based therapies 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3
... in Mexico support innovations to extend the local, productive impact of remittances shines spotlight ... ... Mexico and the US. - Broad, support in communities of origin for the ... from the US. -, Family members in Mexico would encourage senders to ...
... bill pending in the,state Senate could address Pennsylvania,s ... thousands who lack health insurance, a top Department,of ... Joined by approximately 250 nursing students and ... Bureau of Professional and,Occupational Affairs Commissioner Basil Merenda ...
... Touch with Reality, MANHATTAN BEACH, Calif., May 7 ... began in 2006 continues,today with open hearings and fact-finding ... of examining how homecare and nursing home,workers in the ... have the greatest strength to win for their families ...
... Final results of sub-analyses of dose-titration study and long-term, ... open-label study presented today, ... seen in children, Attention Deficit Hyperactivity Disorder,(ADHD) is now known to ... the lifespan(1). In the US, the overall,prevalence of ADHD in adults ...
... For the first time, researchers from the University of ... dendritic cells that are key to asthma and allergy-related ... more effective drugs to treat allergic disorders and asthma, ... of the journal Nature Medicine. , Dendritic cells are ...
... on Hemoglobin-Based Oxygen Carriers Indicates Support for Continued ... Investigational Use Where Blood Is Not an Option, ... BPUR ) announced today that the Company,s strategy to ... HBOC-201, when blood is not an option was reinforced ...
Cached Medicine News:Health News:Recipients in Mexico Favor Receiving US-Sent Remittances Through Companies that Contribute to Local Economic Development and Job Creation Projects 2Health News:Recipients in Mexico Favor Receiving US-Sent Remittances Through Companies that Contribute to Local Economic Development and Job Creation Projects 3Health News:Providing Affordable Health Care Coverage Cited as a Top Priority, Commissioner Says 2Health News:Open Hearings, Fact-Finding Today by SEIU Long Term Care Workers Continues Democratic Process Begun in 2006 2Health News:OROS(R) Methylphenidate in Adults with ADHD: New Insights 2Health News:OROS(R) Methylphenidate in Adults with ADHD: New Insights 3Health News:OROS(R) Methylphenidate in Adults with ADHD: New Insights 4Health News:OROS(R) Methylphenidate in Adults with ADHD: New Insights 5Health News:OROS(R) Methylphenidate in Adults with ADHD: New Insights 6Health News:Immune system pathway identified to fight allergens, asthma 2Health News:Biopure Reaffirms Strategy Following Recent NIH/FDA Workshop 2Health News:Biopure Reaffirms Strategy Following Recent NIH/FDA Workshop 3Health News:Biopure Reaffirms Strategy Following Recent NIH/FDA Workshop 4
... bags are part of the Freedom ... of leg bags, kits, and accessories ... of our customers. These leg bags ... constructed of 100% latex-free soft, textured ...
... part of the Freedom Urinary Collection ... bags, kits, and accessories designed to ... customers. These leg bags are offered ... 100% latex-free soft, textured medical grade ...
... Freedom leg bags are part of ... versatile line of leg bags, kits, ... varied needs of our customers. These ... sizes, and constructed of 100% latex-free ...
The latex-free, PVC-free Antibacterial Hydro Personal catheter combines two remarkable innovations into one exclusive catheter that delivers an antibacterial agent while providing the virtually frict...
Medicine Products: